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Abstract
HIV-1 Vpr is a virion-associated protein. Its activities link to viral pathogenesis and disease progression of HIV-infected
patients. In vitro, Vpr moderately activates HIV-1 replication in proliferating T cells, but it is required for efficient viral
infection and replication in vivo in non-dividing cells such as macrophages. How exactly Vpr contributes to viral replication
remains elusive. We show here that Vpr stimulates HIV-1 replication at least in part through its interaction with hHR23A, a
protein that binds to 19S subunit of the 26S proteasome and shuttles ubiquitinated proteins to the proteasome for
degradation. The Vpr-proteasome interaction was initially discovered in fission yeast, where Vpr was shown to associate
with Mts4 and Mts2, two 19S-associated proteins. The interaction of Vpr with the 19S subunit of the proteasome was further
confirmed in mammalian cells where Vpr associates with the mammalian orthologues of fission yeast Mts4 and S5a.
Consistently, depletion of hHR23A interrupts interaction of Vpr with proteasome in mammalian cells. Furthermore, Vpr
promotes hHR23A-mediated protein-ubiquitination, and down-regulation of hHR23A using RNAi significantly reduced viral
replication in non-proliferating MAGI-CCR5 cells and primary macrophages. These findings suggest that Vpr-proteasome
interaction might counteract certain host restriction factor(s) to stimulate viral replication in non-dividing cells.
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Introduction
HIV-1 viral protein R (Vpr) is a virion-associated protein with
an average length of 96 amino acids (,15 kD). Vpr displays
several distinct activities in host cells, including cytoplasmic-
nuclear shuttling [1], induction of cell cycle G2 arrest [2] and cell
killing [3]. The cell cycle G2 arrest induced by Vpr is thought to
suppress human immune functions by preventing T cell clonal
expansion [4] and to provide an optimized cellular environment
for maximal levels of viral replication [5]. Vpr-induced G2 arrest
also leads to apoptosis. It is unclear at present what is the
biological significance of this effect but it may contribute to the
depletion of CD4+ T cells in HIV-infected patients [6]. The
cytoplasmic-nuclear shuttling is believed to contribute to nuclear
transport of the viral pre-integration complex (PIC)[1,7].
HIV-1 Vpr contributes to viral replication at least in two
different ways. First, in proliferating cells, Vpr promotes viral
replication by blocking cell proliferation of HIV-infected T-cells
and arresting them in G2 phase of the cell cycle, where the viral
replication reaches maximal levels [5]. Contribution of Vpr to
viral replication in proliferating T-cells, however, is relatively small
in vitro as depletion of vpr gene from the viral genome typically
results in a 2–4 fold reduction of viral replication [5]. On the other
hand, Vpr is essential for efficient viral replication in non-dividing
cells such as macrophages [8]. Why the requirement for Vpr
differs in these two cell types is not well understood.
Noticeably, a recent paper showed that the differential
requirement for Vpr is not due to the cell proliferation status, as
infection of arrested T-cells by Vpr(2) HIV-1 reduced viral
replication by 2-fold compared to Vpr(+) virus [9], which is
essentially the same level of reduction observed in proliferating
cells. In addition, Vpr participates in nuclear import of PIC in T
cells in a similar manner as it does in macrophages, and nuclear
import through the nuclear pore is essential for HIV replication in
both cell types [10].
Recently, several reports demonstrated that the activity of Vpx,
an SIV protein similar to Vpr, stimulates reverse transcription by
counteracting a yet unidentified cellular restriction factor [11,12].
Interestingly, expression of Vpx stimulates replication in macro-
phages not only of lentiviruses, including HIV-1, but also gamma
retroviruses such as MLV [13]. The finding that Vpx stimulates
replication in macrophages of Vpr-expressing HIV-1 [11,12]
suggests that either Vpr is a weak inhibitor of a Vpx-targeted
restriction factor, or that Vpr may target other host restriction
factors that are different from those targeted by Vpx. The ability of
Vpx to counteract the restriction of HIV-1 and SIV infection in
macrophages depends on DDB1, a subunit of the VprBP-
associated E3 ligase [11,12]. A DDB1-Vpr fusion could partially
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may work in concert with an ubiquitin-proteasome system to limit
cellular restriction factor(s) that is normally resistant to HIV
infection in macrophages.
The proteasome (or 26S proteasome) is a large multi-subunit
protein complex, which is made up of two distinct subcomplexes,
the 20S catalytic core and the 19S regulatory cap [14]. The
proteasome is responsible for ubiquitin (Ub)-mediated protein
degradation. Proteins are targeted for degradation by the addition
of a highly conserved poly-Ub chain, which is covalently attached
to substrate proteins by a cascade system consisting of activating
(E1), conjugating (E2), and/or ligating (E3) enzymes. An excision
DNA repair Rad23 family proteins, including fission yeast Rhp23
[15] and human hHR23A/Rad23A, shuttle poly-Ub substrates to
the proteasome for degradation [16]. Specifically, the Rad23
family proteins carry an ubiquitin-like (UbL) and two ubiquitin-
associated (UbA) domains. A number of reports demonstrated that
the UbA domains are important for binding of poly-Ub proteins
whereas the UbL domain binds to proteasome [17]. However, it is
currently unknown whether the role of hHR23A in promoting
proteolysis is universal to all poly-Ub proteins or is specific to a
subset of functionally relevant target proteins. During proteolysis,
the 19S cap unfolds the Ub-tagged substrates and translocates
them into the 20S catalytic core, where the proteins are degraded.
In this study, we took a unique approach in testing the
interaction of Vpr with cellular proteins. Specifically, we started by
using a fission yeast model system to search for genetic suppressors
against nuclear import capacity of Vpr [18,19]. Among other
findings using this model system [20–22], one of the most
intriguing discoveries was that Vpr interacts with the 19S
proteasome through Rhp23/hHR23A. This was further con-
firmed by the fact that depletion of hHR23A interrupts interaction
of Vpr with proteasome. Furthermore, Vpr promotes protein poly-
ubiquitination via hHR23A. Most significantly, down-regulation of
hHR23A reduces viral replication in non-dividing MAGI cells and
macrophages, suggesting that hHR23A-mediated interaction of
Vpr with proteasome plays an important role in viral replication in
these non-dividing cells.
Results
Interaction of Vpr with the 19S regulatory subunit of the
proteasome
Vpr can be displaced from the nuclear membrane in
fission yeast by overexpression of cellular proteins that
are associated with the 19S regulatory subunit of the
proteasome. Association of Vpr with nuclear envelope has
been previously described by laboratories including ours both in
fission yeast and mammalian cells [23–27]. The initial hint that
Vpr interacts with proteasomes came from our search in fission
yeast for multicopy suppressors of Vpr localization on nuclear
membrane, an indication of the nuclear transport capacity of Vpr
[28]. To search for such suppressors, a fission yeast cDNA library
was expressed in the fission yeast RE078 strain containing a
single copy of gfp-vpr gene integrated in the chromosome [29].
Approximately 2.0610
4 transformants, which statistically cover
the entire yeast genome, were individually screened, and 21
unique clones were found to interfere with the nuclear localization
of Vpr. Significantly, 8 of those clones encode proteins that
associate with the 19S subunit of proteasome either directly
(Rad25, Hsp70, Moc2, Pad1, Wos2 and Skp1) or indirectly (Uch2
and Phlp1) [30,31]. As shown in Fig. 1A, cells expressing GFP-
Vpr had intense green fluorescence at the nuclear rim with little
labeling of the cytoplasm (Fig. 1A, top left). This pattern of
nuclear membrane localization of Vpr observed in fission yeast
cells has been reported previously, which is very similar to that
observed in mammalian cells [20,27,32]. However, overexpression
of Uch2 redistributed Vpr to the cytoplasm (Fig. 1A, top right).
Similar displacement effects were also observed with other 19S-
associated proteins (data not shown). These results indicate that
overexpression of 19S proteasome-associated proteins affect Vpr
localization, suggesting a possible association between proteasomes
and Vpr.
Vpr detaches from the nuclear envelope when the
proteasomes move away from the nuclear membrane. It
has been well established that fission yeast proteasomes localize
predominantly to the nuclear envelope during mitosis in wild-type
yeast, but move away from the nuclear envelope to the cytoplasm
in a cut8 mutant strain [33,34]. If Vpr associates with proteasomes
on the nuclear membrane, it should also move away from the
nuclear rim to the cytoplasm in the cut8 mutant. To test this
assumption, the localization of proteasomes (by using Mts4 as an
indicator) and Vpr was monitored in live cells of the cut8 mutant
expressing the GFP-Vpr and GFP-Mts4 fusions. Mts4 encodes the
subunit 2 (S2) of the 19S regulatory complex of the 26S
proteasome [35] and it has been previously shown that Mts4
falls off the nuclear envelope along with the proteasome in the
non-permissive temperature in the cut8 mutant [33,36]. As shown
in Fig. 1B, both Vpr and Mts4 localized predominantly on the
nuclear membrane at the permissive temperature of 25uC, when
cut8 cells behave like wild type cells. In contrast, at the non-
permissive temperature of 37uC, Mts4 falls off the nuclear
membrane as expected [Fig. 1B, bottom left; [33,36]]. Similar
to Mts4, predominant localization of Vpr to the nuclear rim is lost
at the non-permissive temperature (Fig. 1B, bottom right),
suggesting that nuclear membrane localization of Vpr correlates
with proteasomes on the nuclear membrane.
The proteasome and Vpr co-migrate during centrifugation
on a glycerol gradient in fission yeast and mammalian
cells. To further test Vpr association with proteasomes,
immunoblot analysis of fractions collected after centrifugation of
cellular extracts of fission yeast (Fig. 1Ci) and HeLa (Fig. 1Cii)
cells on a glycerol gradient was performed. Fractionation on such
gradient results in localization of the proteasome subunits in
characteristic fractions [34]. Vpr, a small 15 kDa protein, is
supposedtobe atthe topofthegradientinitsfreeform,butmuchof
the Vpr consistently migrated into the gradient and co-migrated
with the 19S subunit fractions and indicated by anti-Mts4 (Fig. 1Ci
and 1Cii).
Confirmation of Vpr-proteasome interaction by co-
precipitation. To test for a directly interaction between Vpr
and proteasomes, a plasmid pSF173 carrying a HA-Vpr fusion
was transfected into a wild type fission yeast strain and co-
immunoprecipitation analysis was carried out with anti-HA
antibodies. The precipitate was tested for Mts2, which is another
subunit of the regulatory 19S complex of the 26S proteasome [35].
As shown in Fig. 1Di, Mts2 was detected in the pull down from
the HA-Vpr-transfected strain (lane 4), whereas no Mts2 was
pulled down in the HA-tag only control strain (lane 2), providing
direct evidence for a physical interaction between Vpr and the
proteasome.
To further confirm the interaction of Vpr and proteasomes in
mammalian cells, the plasmids pcDNA3-HA-Vpr and pcDNA3-
HA-Kir2.1, which contains an irrelevant HA-Kir2.1 fusion protein
as control, were transfected into HeLa cells. The co-IP of HA-tag
proteins were carried out with anti-HA antibody 48 hrs p.t. The
precipitates were analyzed using anti-S2 and anti-S5a antibodies,
both of which are components of the 19S subunit of the 26S
Vpr-Proteasome Interaction
PLoS ONE | www.plosone.org 2 June 2010 | Volume 5 | Issue 6 | e11371proteasome [37]. In particular, S5a binds to hHR23A, a protein
that was shown previously to bind Vpr [37]. As shown in
Fig. 1Dii, both S2 and S5a were pulled down from pcDNA3-HA-
vpr expressing HeLa cells, whereas no S2 or S5a was detected in
control cells expressing Kir2.1.
In a reciprocal experiment, a pSG5-b1-ZZ plasmid, which
contains an A-ZZ-tagged b1 subunit of the proteasome [38], or a
control plasmid was co-transfected with pcDNA3-HA-Vpr into
HeLa cells. The A-ZZ-tagged proteins were precipitated with anti-
protein A antibody 48 hrs p.t. The pull-down cellular products
were analyzed for Vpr by using anti-HA antibody. As shown in
Fig. 1Diii, HA-Vpr was pulled down only in the A-ZZ-b1-
expressing cells. Taken together, the above data provide strong
evidence for specific interaction of Vpr with the 19S subunit of the
proteasome in fission yeast and mammalian cells.
Vpr binds to 19S proteasome via hHR23A
Interaction of Vpr with a fission yeast homologue Rhp23
of hHR23A. Earlier studies demonstrated a physical interaction
between Vpr and hHR23A, a human protein that contains a N-
Figure 1. Vpr associates with proteasome in fission yeast and mammalian cells. A. Vpr is displaced from the nuclear membrane by
overproduction of Uch2. Fission yeast cells carrying or not carrying Uch2 were stained with DAPI 17 hrs after vpr gene induction. Green color, GFP;
Blue color, nuclear DNA. B. Vpr is displaced from the nuclear membrane in the cut8 mutant. Mts4, a fission yeast homologue of mammalian S2, is a
19S proteasome-associated protein. Cut8 displays normal phenotype at the permissive 25uC, but shows mutant phenotype at non-permissive 37uC.
C. Co-migration of Vpr with proteasome in fission yeast cells (i) and HeLa cells (ii) analyzed by glycerol gradient. Extracts from fission yeast cells
expressing vpr were fractionated by centrifugation on a 10–40% glycerol gradient. Equal amounts of proteins from each fraction of the gradient were
separated on 12% SDS-PAGE and probed with antibodies against Vpr and 19S (Mts4) subunits of the proteasome [34]. Lanes 1–8 indicates different
fractions collected from the top (low molecular weight) to bottom of the gradient (high molecular weight). Note that not all fractions are shown here.
D.i. Co-immunoprecipitation shows interaction of Vpr with Mts2 in yeast cells. IP was carried out with anti-HA as described previously [59]. A HA-tag
alone plasmid control was used in this experiment. The recovered proteins were fractionated on SDS-PAGE and immunoblotted with anti-HA, anti-
Vpr and anti-Mts2 antibodies. CL, cell lysates; IP:HA, immunoprecipitation with a HA-tagged control plasmid; IP:HA-Vpr, immunoprecipitation witha
HA-Vpr carrying plasmid. ii. HeLa cells were transfected with HA-Vpr or HA-Kir2.1 (control). Kir2.1 is an irrelevant protein to Vpr and used here as a
control. IP was carried out with anti-HA, recovered proteins were fractionated on SDS-PAGE and immunoblotted with anti-S2 (a mammalian
homologue of fission yeast Mts4) and anti-S5a antibodies. iii. HeLa cells were co-transfected with pSG5-ZZ-b1, which codes for a proteasomal
b1subunit [38], or control pSG5-ZZ plasmid (Ctr) together with HA-Vpr. The protein A-tagged b1 or control protein were pulled down by anti-protein
A antibody, then blotted with anti-HA antibody.
doi:10.1371/journal.pone.0011371.g001
Vpr-Proteasome Interaction
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analysis of this interaction indicated that Vpr binds to hHR23A
through its C-terminal UbA domain [40]. Previous studies on this
protein and its budding yeast orthologue Rad23 showed that
hHR23A homologues bind to the proteasome via the N-terminal
UbL domain [41,42]. However, the biological function(s) of the
Vpr-hHR23A interaction and the significance of UbA or UbL
interactions with Vpr or proteasome during the Vpr-hHR23A
were unknown. To address these questions, we cloned and
characterized a fission yeast orthologue (Rhp23) of human
hHR23A [15]. Same as hHR23A, Rhp23 also contains both the
N-UbL and the two C-UbA domains. Consistent with the Vpr-
hHR23A interaction, using the yeast two-hybrid system we
demonstrated that Rhp23 also binds to Vpr through the UbA
domain [Fig. 2Ai]. Furthermore, in vitro interaction of Vpr with
Rhp23 was further verified by incubating the bacterial cell lysates
over-expressing GST or GST-Vpr protein with 35S-labeled
Rhp23:Rhp23 bound only to GST-Vpr protein (Fig. 2Aii).
Same as hHR23A, Rhp23 also associates with
proteasome. To confirm the association of Rhp23 with
proteasome in fission yeast, a plasmid containing HA-tagged
Rph23 was transfected into fission yeast with or without vpr
expression. Following immunoprecipitation with anti-HA
antibody, anti-Mts4, which recognizes the S2 subunit of the 19S
regulatory complex of the proteasome, was used to detect
proteasome. As shown in Fig. 2B, Mts4 protein was detected in
the HA-Rph23 pulled down protein complexes regardless of
whether Vpr was absent or present (Fig. 2B, lanes 2,3).
Depletion of hHR23A by siRNA reduces binding of
Vpr to proteasome. Since Vpr appeared to interact with
proteasome through Rhp23 or hHR23A in fission yeast and
mammalian cells, we were interested in determining whether
hHR23A is indeed required for Vpr interaction with 26S
proteasome. The same experiment as shown in Fig. 1Dii was
repeated, except that hHR23A was also depleted in one of the
samples using siRNA. Specifically, the pcDNA3-HA-Vpr was
transfected into HeLa cells with or without hHR23A mRNA
knockdown by specific siRNA. Co-IP of HA-tagged proteins was
conducted using anti-HA antibody and presence of proteasome in
the precipitates was detected using anti-S2 and anti-S5a
antibodies. As expected, both S2 and S5a were detected in the
pull-down protein extracts of vpr-expressing HeLa cells (Fig. 2Ci,
lane 2). In contrast, little or no S5a and S2 were seen in the
hHR23A-depleted cells (Fig. 2Ci, lane 3). Depletion of hHR23A
was confirmed by Western blot analysis (Fig. 2Cii). Together,
these data suggest that Vpr binds to 19S complex of proteasome at
least in part through hHR23A.
Vpr promotes protein poly-ubiquitination via hHR23A.
Since Vpr interacts with proteasome through hHR23A, we
were interested in learning the potential effect of Vpr on the role
of hHR23A in protein poly-ubiquitination. To address this
question, the Flag-tagged hHR23A was co-expressed with HA-
ubiquitin in the presence or absence of Vpr in HeLa cells. Forty-
eight hours after transfection, cells were collected and cell extracts
were subjected to Western blot analysis using anti-HA antibody.
The Flag-tagged hHR23A(c57), a mutant derivative of hHR23A
that contains only the COOH-terminal 57 amino acid residues
[43], was used as a negative control. Same as in fission yeast (data
not shown), expression of hHR23A significantly increased the
amount of poly-Ub in comparison with cells expressing the
hHR23A(c57) mutant (compare lane 3 to lane 1 in Fig. 2D).
This hHR23A-mediated poly-Ub was further enhanced by a
proteasome inhibitor, MG132 (compare lanes 3 and 5 in
Fig. 2D). Thus the expression of Vpr appeared to promote
hHR23A-mediated protein poly-Ub (Fig. 2D, lanes 2, 4 and 6).
The low level of ubiquitination in cells transfected with
hHR23A(c57) mutant was likely mediated by endogenous
hHR23A. Together, these data support the notion that Vpr
promotes protein poly-Ub via hHR23A.
Depletion of hHR23A significantly reduced HIV-1
replication in a Vpr-dependent fashion. Since HIV replication-
stimulating activity of Vpr is most evident in non-dividing cells [1,44],
we decided to first compare the potential effect of hHR23A depletion
on Vpr-dependent viral replication in proliferating and non-dividing
cells. hHR23A was knocked down in MAGI-CCR5 cells using siRNA
(control cells were treated with control siRNA), cells were transferred
from high (10% FBS) to low serum (0.1% FBS) to stop cell proliferation
[45] and both proliferating and non-dividing cells were then infected
by Vpr-positive (Vpr+)o rV p r - n e g a t i v e( V p r 2)H I V - 1 Ada.T h ec e l l
proliferation status in high or low serum was examined by
measuring growth curves. As shown in Fig. 3Ai, MAGI cells
cultured in normal high serum proliferated exponentially as
expected; in contrast, no growth was detected over a period of 5
days after MAGI cells were transferred to 0.1% FBS. Even
though serum-starved cells showed no cellular proliferation, no
obvious cell death was observed as all the cells remained adherent
to the bottom of the culture plates (data not shown).
For HIV-1 infection, both control and hHR23A-depleted cells
were infected with HIV-1Ada Vpr(+) or Vpr(2) virus with TCID50
of 3,000 24 hrs after the hHR23A knockdown. Viral replication
was evaluated 48 hrs after infection by staining for X-Gal
expression; blue cells were counted as infected cells. To avoid
potential biases in counting HIV-infected blue cells, 4 independent
experiments were carried out and each experiment was counted
independently by two individuals. As shown in Fig. 3Aii, there are
no significant differences in the levels of viral replication between
wild type and hHR23A-depleted cells in normally proliferating
cells; as expected, a small but appreciable decrease of viral
replication was seen in cells infected with Vpr(2) virus. In the non-
proliferating cells, however, there were profound differences in the
level of viral replication between Vpr(+) and Vpr(2) viruses.
Replication of the Vpr-negative virus was about 90% lower than
of the Vpr(+) HIV-1. Most significantly (p,0.05), depletion of
hHR23A reduced replication of the Vpr(+) virus by over 65%
(Fig. 3Aii), whereas no effect was observed on replication of the
Vpr(2) HIV-1.
We next performed a similar experiment with monocyte-
derived macrophages. The isolated macrophages were transfected
with hHR23A siRNA or control siRNA, infected with HIV-1Ada
(Vpr+)a n d( V p r 2) viruses, and transfected again. Cells were
collected 72 hrs p.i. and HIV-1 replication was determined by
measuring p24. The observed reduction of viral replication due to
hHR23A was depicted as the % of inhibition rate. As shown in
Fig. 3Bi, while no obvious effect of hHR23A suppression was
found in macrophages infected with the Vpr(2) viruses,
hHR23A-depleted cells showed an approximately 40% reduction
of viral replication (p,0.05). Successful downregulation of
hHR23A mRNA was demonstrated by Western blotting using
anti-Rad23A antibody (Fig. 3Bii). Note that statistically
significant differences were found in the hHR23A knock-down
cells in MAGI-CCR5 (Fig. 3Aii) and macrophages (Fig. 3B).
Time-course experiments with multiple MOIs were not con-
ducted. Thus contribution of hHR23A under other experimental
conditions is unknown.
Together, results of these experiments strongly suggest that the
stimulating effect of Vpr on HIV-1 replication in non-dividing cells
is due, at least in part, to hHR23A-mediated Vpr-proteasome
interaction.
Vpr-Proteasome Interaction
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In this study, we have demonstrated for the first time that Vpr
interacts directly with the 26S proteasome. We have further shown
that this interaction is linked to the regulatory 19S subunit of the
proteasome through hHR23A, a Vpr-binding protein that is
capable of shuttling ubiquitinated proteins to the proteasome for
degradation [16]. Our results further show that Vpr promotes
protein-ubiquitination, thus it may potentially lead to enhanced
protein degradation of the downstream targets. While those
downstream targets are currently unknown, it is clear that this
hHR23A-mediated interaction of Vpr with proteasome plays a
Figure 2. hHR23A is critical for Vpr-proteasome interaction. A. In vitro and in vivo interactions of Rhp23 with HIV-1 Vpr. (i) Rhp23, a fission
yeast homologue of mammalian hHR23A[15], interacts with Vpr in the yeast two-hybrid system. The vpr gene was inserted into the pGBT9 plasmid
and rph23 was fused to the activation domain in the pGAD-GH plasmid. The interaction was measured by b-galactosidase assay on cell extracts. (ii) In
vitro interaction of Vpr with Rhp23. Bacterial cell lysates over-expressing GST and GST-Vpr proteins were immobilized on GST-agarose beads. In vitro
translated 35S-labeled Rhp23 (shown by arrow) was incubated with the immobilized GST and GST-Vpr. The Coomassie staining (low panel) shows
total proteins, and autoradiography (top panel) shows bound 35S-labeled Rhp23. B. Interaction of Rph23 with proteasome in the presence or
absence of Vpr. HA-Rhp23-carrying plasmid was transfected into fission yeast in the presence or absence of Vpr. Following immunoprecipitation with
anti-HA antibody, precipitates were tested with anti-Mts4, which recognizes the 19S regulatory subunit of the proteasome. C.i. Depletion of hHR23A
abolished the interaction of Vpr with proteasome in HeLa cells. The HA-Vpr or HA-Kir2.1 (control) expressing vectors were transfected into HeLa cells
with (lane marked 23A) or without hHR23A depletion by siRNA. The HA-tagged proteins were pulled down by anti-HA antibody, and then blotted
with anti-S2 and anti-S5a antibodies, which recognize S2 and S5a, respectively, of the 19S regulatory subunits of the proteasome. ii.5 0mgo f
supernatants from lanes 2 (None) and 3 (23A) of a were blotted with anti-Rad23A or b-actin antibody. D. Vpr promotes protein poly-ubiquitination
via hHR23A. Flag-tagged hHR23A was co-expressed with HA-ubiquitin in the presence or absence of Vpr in HeLa cells. Forty-eight hours after
transfection, cells were collected and cell extracts were subject to Western blot analysis using indicated antibodies. hHR23(c57) is a non-functional
mutant derivative of hHR23A [43]. MG132 was used to inhibit the proteasome activities.
doi:10.1371/journal.pone.0011371.g002
Vpr-Proteasome Interaction
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CCR5 cells and primary macrophages.
The major function of the 26S proteasome is to digest proteins
that are tagged for degradation. During host-pathogen interac-
tions, the proteasome-mediated proteolysis is often used both by
host cells to restrict viral infection and/or by the pathogen to
counteract host restriction. For example, proteasome-mediated
proteolysis is involved in the host cell MHC class I antigen
presentation for viral antigen processing. The viral proteins are
broken down by the proteasome so that the viral epitopes can be
recognized by CD8 T-lymphocytes to trigger cytotoxic T-
lymphocyte (CTL) response, a process that specifically destroys
the infected cells. Conversely, proteasome-mediated proteolysis is
also required for viral survival and pathogenesis. HIV-1 Tat
protein binds to the 26S proteasome and inhibits its activity [46].
Similarly, SIVSM/HIV-1 Vpx proteins promote retroviral escape
from a proteasome-dependent restriction pathway present in
human dendritic cells [47].
Several HIV-1 proteins are known to be involved in protein
degradation through mediation of protein ubiquitination via
binding to Ub E3 ligases. For example, HIV-1 Vif is known to
promote degradation of the host cellular antiviral factor,
APOBEC3G, through interaction with a Cullin5-ElonginBC Ub
E3 ligase complex [48,49]. Similarly, Vpr binds to a specific Cullin
Cul4A-DDB1-DCAF1/VprBP ubiquitin E3 ligase for induction of
cell cycle G2 arrest in proliferating cells [50,51]. Thus, it is possible
that Vpr may facilitate degradation of a specific subset of target
proteins by first engaging the VprBP-associated E3 ligase for
protein tagging with Ub; the ultimate protein degradation might
be mediated by Vpr, for example, through shuttling of
ubiquitinated proteins to proteasome via hHR23A.
Binding of Vpr to hHR23A has been reported previously [37].
Earlier studies on the interaction of Vpr with hHR23A suggested
that this interaction might play a role in the induction of G2 arrest
[37,39], but mutational analysis did not support this interaction
[52]. Thus, the functional role of Vpr-hHR23A interaction in
Figure 3. hHR23A is required for Vpr-mediated stimulation of HIV-1 replication in non-dividing MAGI-CCR5 cells and macrophages.
A.i. Cell proliferation of MAGI-CCR5 cells in different FBS concentration. MAGI-CCR5 cells were plated at 7,000 cells/well in DMEM containing 10% or
0.1% of FBS. Cellular proliferation was measured over a period of 5 days. Cells in 0.1% FBS were viable over the experimental period, as they remained
adherent to plates. ii. Depletion of hHR23A significantly reduces viral replication in non-dividing MAGI cells in a Vpr-dependent manner. MAGI-CCR5
cells were transfected with hHR23A-targeting (+) or control (2) siRNA, plated in DMEM with 10% or 0.1% FBS, and infected with HIV-1Ada Vpr(+)o r
Vpr(2) 24 hrs after hHR23A knockdown. Viral replication was evaluated 48 hrs after infection by staining; blue cells were counted as infected. Results
are presented as percent of control, i.e., the number of blue cells in cultures transfected control siRNA and infected with Vpr-positive HIV-1 and show
average 6 SE of quadruplicate determinations. B. Vpr-dependent HIV-1 viral replication in macrophages is mediated through hHR23A. i. Monocyte-
derived macrophages pretreated with hHR23A siRNA or control (Ctr) siRNA were infected with HIV-1Ada (Vpr+) or (Vpr2) viruses. Cells were collected
72 hrs p.i. and viral replication was determined by measuring p24. Results are presented as inhibition of HIV-1 replication in cells treated with hHR23A
siRNA relative to cells treated with control siRNA, and show mean 6 SE of three independent experiments with cells from different donors, each
performed in triplicate. Statistical analysis was performed using Student’s t-test, and p value is shown. ii. Monocyte-derived macrophages were
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report suggest that the Vpr-hHR23A interaction might be
involved in proteasome-mediated proteolysis. Interestingly, while
we were preparing for this report, a new report came out [53] and
showed that Vpr induces protein polyubiquitination of unknown
proteins through direct protein-protein interactions. Furthermore,
these interactions appear to correlate with Vpr-induced cell cycle
G2 arrest and the proteasome activity. G2-arrest-defective
mutants of Vpr decreased those interactions; whereas inhibition
of proteasomal activity enhanced them. Thus, it would be of great
interest to test whether hHR23A is among those polyubiquitinated
proteins and further to re-visit its role in Vpr-induced G2 arrest. It
should be mentioned that this recent report [53] did not show
direct interaction of Vpr with proteasome and the specific
involvement of hHR23A in this interaction. Thus, we believe
that interaction of Vpr with hHR23A may underlie a new
biological activity of Vpr in which Vpr associates with and affects
the activity of the proteasome.
One of the most intriguing findings of this study is the
contribution of hHR23A-Vpr interaction to viral replication in
non-dividing cells but not in proliferating cells (Fig. 3). Even
though requirement of Vpr in HIV-1 infection of non-dividing
cells is not new [8], the molecular action of Vpr in this process is
not well understood. It has been long believed that the reason why
Vpr is required for viral replication in cells such as macrophages is
that Vpr promotes nuclear import of PIC in non-dividing cells [1].
However, a recent study demonstrated that the differential
requirement of Vpr may not be due to the cell proliferation status
[9]. In addition, Vpr also participates in nuclear import of PIC in
T cells in a similar manner as it does in macrophages, and nuclear
import through the nuclear pore is essential for HIV replication in
both cell types [10]. An alternative possibility is that cellular factors
that either regulate Vpr or are regulated by Vpr may differ
between proliferating and non-proliferating cells and thus
determine whether Vpr is needed. For example, expression of a
cellular factor HSP70, which can substitute for the nuclear import
activity of Vpr, is higher in T-cells than in macrophages, thus
diminishing dependence of viral replication on Vpr in T-cells [54].
Several recent reports demonstrate that the activity of Vpx, also
limited to macrophages, stimulates reverse transcription by
counteracting a yet unidentified cellular restriction factor
[11,55]. Vpx is absolutely essential for SIV replication in
macrophages, and expression of Vpx stimulates replication in
these cells in the context of a number of retroviruses, including
HIV-1 and MLV [13]. The finding that Vpx stimulates replication
in macrophages of Vpr-expressing HIV-1 [11] suggests that either
Vpr is a weaker inhibitor of a Vpx-targeted restriction factor, or
that Vpr’s target is different from that of Vpx. Interestingly, HIV-2
Vpx binds to the same VprBP-associated E3 ligase as HIV-1 Vpr
to overcome restriction factors in macrophages [11,12,55]. The
ability of Vpx to counteract the restriction of HIV-1 and SIV
infection depends on DDB1, a subunit of the VprBP-associated E3
ligase. A DDB1-Vpr fusion could partially substitute for the role of
Vpx [11]. These findings are consistent with our model that Vpr
may work in concert with an ubiquitin-proteasome system to limit
cellular factor(s) restricting HIV replication in non-dividing cells:
interaction with such factors as DDB1 (for Vpx) or hHR23A (for
Vpr) may define the target and fine-tune the viral protein activity.
Thus, we propose that Vpr plays a role similar to that of Vpx,
i.e., it promotes inactivation of a restriction factor expressed in
macrophages and some non-dividing cells through an ubiquitin-
proteasome process. Fig. 4 depicts a working model to describe
our current understanding of the role Vpr-hHR23A interaction
plays in Vpr-mediated stimulation of HIV-1 replication in
macrophages. First, cellular proteins may be targeted by Vpr via
binding of these proteins to the Vpr-VprBP-associated E3 ligase
complex, in which VprBP is an adaptor protein for the E3 and is
responsible for the substrate specificity. Second, Vpr interaction
with hHR23A fine-tunes the binding of hHR23A UbA domains to
poly-Ub proteins, which are subsequently shuttled to the 26S
Figure 4. Proposed model of Vpr-proteasome interactions. Details are in the text.
doi:10.1371/journal.pone.0011371.g004
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Upon receiving the Ub-tagged proteins, the 19S cap of the
proteasome unfolds the Ub-tagged target proteins and translocates
them into the 20S catalytic core, where the proteins are ultimately
degraded. We propose that the repertoire of proteins targeted by
Vpr through this mechanism differs between different cell types,
and specifically between T cells and macrophages, thus explaining
a more potent effect of Vpr in the latter cells. Results generated
from testing this working model will provide additional insights
into the specific role of Vpr in viral replication.
Materials and Methods
Yeast strains and mammalian cells
All of the Fission yeast (Schizosaccharomyces pombe) strains, human
cell lines, plasmids and HIV-1 viral stocks used in this study are
shown in Table 1. Yeast cells were grown in complete medium
containing adenine (YEA) or Edinburgh minimal medium (EMM)
by using standard culture techniques [56]. Human HeLa cells and
MAGI-CCR5 cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (Cellgro) supplemented with 10% fetal
bovine serum (FBS, Invitrogen). Human monocyte-derived
macrophages were prepared from peripheral blood mononuclear
cells by plastic adherence and cultivated using standard techniques
as described previously [44].
Gene expression in fission yeast cells
Gene induction under the control of the fission yeast nmt1
promoter in liquid medium has been described previously [56].
Briefly, cells containing the plasmid with the nmt1 (no message in
thiamine) promoter were first grown to stationary phase in the
presence of 20 mM thiamine. Cells were then washed three times
with distilled water, diluted to a final concentration of approxi-
mately 2610
5 cells/ml in 10 ml of the appropriately supplemented
EMM medium with or without thiamine. Cells were examined
24 hours after gene induction. All cells were normally grown at
30uC with constant shaking at 200 rpm unless otherwise specified.
Transfection of mammalian cells with plasmids and
siRNA
All of the plasmids were transfected into cells by using
Lipofectamine 2000 following manufacture’s instructions (Invitro-
gen). HPLC-purified siRNAs commercially designed to specifically
target hHR23A (Cat. No. SI02663654), and control non-silencing
siRNA (Cat. No. 1022083) were purchased from Qiagen (Valen-
cia, CA). The siRNA mixture was transfected at a concentration of
10 nM into approximately 5610
5 HeLa cells by use of 8 mlo f
Lipofectamine RNAiMAX following manufacturer’s instructions
(Invitrogen). Measurement of transfection efficiency by using
Rhodamine labeled siRNA indicated an efficiency of over 90%
(data not shown).
For transfection of primary monocyte-derived macrophages,
1610
6 cells were incubated with 150 pmol of siRNA and 7 ml
metafectene (Biontex) in Opti-MEM (Gibco) at 37uC for 3–
5 hours. On day 2, cells were infected with HIV-1Ada, and on day
3 transfection procedure was repeated.
Fluorescence microscopy
A Leica DMR fluorescence microscope (DM4500B; Leica
Microsystems) equipped with a high-resolution camera (Hama-
matsu) and OpenLab software (Improvision) was used for all of the
Table 1. Fission yeast strains, human cell lines, plasmids and HIV-1 viral stocks.
Strains/Plasmids Genotype and Characters Source or Reference
S. pombe strains:
SP223 Wild type, h
2, ade6-216, leu1-32, ura4-294 [26]
RE078 SP223 with single copy of gfp-vpr integrated at ura4 locus; used for determining
nuclear localization of Vpr
[20]
Cut8 h-, leu1, ura4, Dcut8::ura4+ [33]
Mammalian cell lines:
HeLa A cervical epithelial cell line ATCC
MAGI-CCR5 A CD4-positive derivative of HeLa cell line; containing an integrated HIV-1 LTR-driven
b-galactosidase reporter gene
NIH AIDS Research and
Reference Reagents Program
S. pombe Plasmids:
pYZ1N Fission yeast expression vector with an inducible nmt1 promoter and a leu1
selectable marker
[26]
pYZ3N Same as pYZ1N but with a 59 GFP-tag [26]
pSF173 Fission yeast expression vector with an inducible nmt1 promoter and a 59 HA-tag, ura4 selectable ATCC
Mammalian plasmids:
pCDNA3.1 Mammalian expression vector with a CMV promoter; hygromycin-resistant Invitrogen
pcDNA3.1-HA-Vpr HA-tagged Vpr on pcDNA3.1 Nathaniel R. Landau
pCDNA3-HA-Kir2.1 HA-tagged Kir2.1., a control plasmid for HA-Vpr Paul Weilling
pSG5-b1-ZZ Proteasomal b1 subunit cloned in the pSG5-ZZ plasmid [38]
pSG5-ZZ A control plasmid for pSG5-b-ZZ [38]
HIV-1 viral stocks:
HIV-1Ada Vpr (+) Packaged virus using the HIV-1 Ada strain with wild type Vpr [20]
HIV-1Ada Vpr (2) Packaged virus using the HIV-1 Ada strain with a mutant Vpr [20]
doi:10.1371/journal.pone.0011371.t001
Vpr-Proteasome Interaction
PLoS ONE | www.plosone.org 8 June 2010 | Volume 5 | Issue 6 | e11371imaging analysis. For analyzing the subcellular localization of
green fluorescent protein (GFP)-tagged fusion proteins in fission
yeast, live cells were observed under a fluorescence microscope
and images were captured 18 to 20 h after vpr gene induction.
Nuclear localization was verified by DNA staining with 1 mgo f
DAPI (49,6 9-diamidino-2-phenylindole)/ml.
Yeast 2-hybrid system
The vpr gene was inserted into the pGBT9 plasmid and rph23
was fused to the activation domain in the pGAD-GH plasmid. The
strength of the interaction was measured by b-galactosidase assays
on cell extracts as described previously [57].
In vitro interaction of Vpr with Rhp23
Bacterial cell lysates over-expressing GST and GST-Vpr
proteins were immobilized on GST-agarose beads. In vitro
translated 35S-labeled Rhp23 was incubated with the immobilized
GST and GST-Vpr. After extensive washes, the bound proteins
were eluted and separated by SDS-PAGE, then subjected to
coomassie staining or autoradiography detection.
Cell lysis and immunoblotting analysis
For fission yeast, cell lysates were prepared by the glass beads
method using lysis buffer (50 mM Tris-HCl, pH 8.0; 50 mM NaF;
1 mM Na3VO4; 5 mM EDTA; 150 mM NaCl; 10% glycerol;
0.1% Triton X-100) supplemented with protease inhibitors as
previously described. Mammalian cells were lysed with lysis buffer
(50 mM Tris, pH 7.5; 150 mM NaCl; 2 mM EDTA; 1% Triton
X-100) on ice for 30 min and the debris was removed by
centrifugation at 13,000 rpm for 1 min. The protein concentra-
tions of supernatants were measured by BCA protein assay kit
(Pierce).
For Western blot analysis, 30 to 50 mg of protein was loaded on
10–20% gradient Criterion Precast Gels (BioRad) for electrophore-
tic separation. Proteins were transferred to the Trans-blotH
Nitrocellulose membranes and blotted with 5% skim milk in TBST
buffer (10 mM Tris, pH 8.0; 150 mM NaCl; 0.1% Tween 20) for
30 min at room temperature. Primary antibodies were then applied
overnight at 4uC. After washing 3 times in TBST for 10 min each
time, the membranes were incubated with secondary antibody for
1 h at room temperature. Membranes were washed again and
proteins were detected with SupersignalH Western Dura Extended
Duration Substrate (Pierce, Rockford, IL)[47]. The following
primary antibodies were used: mouse monoclonal anti-hemagglu-
tinin antibody (anti-HA; HA-7, Sigma), mouse monoclonal anti-
Flag antibody (M2, Sigma), mouse monoclonal anti-b-actin
antibody (AC-15, Sigma), rabbit polyclonal anti-Protein A antibody
(Sigma), rabbit polyclonal anti-19S proteasome S2 subunit antibody
(Calbiochem), rabbit polyclonal anti-19S proteasome S5a antibody
(Calbiochem), rabbit anti-Rad23A antibody (H-87, Santa Cruz
Biotechnology); rabbit polyclonal anti-Ubiquitin antibody (Cell
Signaling); rabbit polyclonal anti-Vpr serum was custom generated
by the Proteintech Group, Inc. (Chicago, IL). Goat anti-mouse
horseradish peroxidase-conjugated and goat anti-rabbit horseradish
peroxidase-conjugated antibodies were used as secondary anti-
bodies (Bio-Rad). Antisera against fission yeast Mts4 and Mts2 were
gift from Dr. Colin Gordon as described previously [35].
Protein co-migration analysis
Co-migration of Vpr with proteasome was analyzed by glycerol
gradient in fission yeast and HeLa cells. Extracts from fission yeast
and HeLa cells expressing vpr were fractionated by centrifugation
on a 10–40% glycerol gradient. Equal amounts of proteins from
each fraction of the gradient were separated on 12% SDS-PAGE
and detected with antibodies against Vpr and 19S subunits of the
proteasome by using anti-Mts4 antibody [58].
Co-immunoprecipitation
The co-immunoprecipitation of HA-tag proteins for fission yeast
were carried out as previously described [59]. Briefly, proteins
were immunoprecipitated from the cell lysates with anti-HA
antibody overnight at 4uC. The protein-antibody complexes were
subsequently collected by adding protein A-agarose beads and
incubated for 2 hrs at 4uC. Immunoprecipitates were then washed
three times with PBS containing protease inhibitors prior to
analysis.
For mammalian cells, the co-immunoprecipitation of HA-
tag proteins was carried out with ProFound Mammalian HA
Tag IP/Co-IP kit according to manufacturer’s instructions
(Cat.No. 23615, PIERCE). Briefly, cells were lysed with M-PER
mammalian protein extraction reagent on ice for 30 min and the
debris was removed by centrifugation at 13,000 rpm for 1 min.
The cell lysate was transferred to spin column and 6 ml anti-HA
agarose slurry was added into each cell lysate. After incubation
with gentle end-over-end mixing overnight, supernatant was
collected into collection tube with pulse centrifugation for 10
seconds. The column containing HA-tagged proteins was washed
three times with 0.5 ml TBST, then eluted with 60 ml of 2X non-
reducing sample buffer at 95–100uC on a heat block for 5 minutes.
The eluted proteins were collected by pulse centrifugation for 10
seconds, and 3 ml of 2-mercaptoethanol was added for SDS-
PAGE.
MAGI assay
MAGI assay was used to determine the viral infectivity. Briefly,
MAGI-CCR5 cells were seeded in 6-well plates at 7,000 cells per
well. On the following day, cells were transfected with specific
siRNA against hHR23A or control siRNA. Both control and
hHR23A-depleted cells were infected with HIV-1Ada Vpr(+)o r
Vpr(2) virus with TCID50 of 3,000 24 hrs after hHR23A
knockdown. The media were removed and cells were fixed by
2 ml fixing solution (1% formaldehyde, 0.2% glutaraldehyde in
PBS) 48 hrs after infection. Viral replication was evaluated by
staining with 600 ml of staining solution (6.6 mM potassium
ferrocyanide, 3.3 mM MgCl2, 0.7 mg/ml X-Gal in PBS). Blue
cells were counted as infected cells in each well under microscope.
Infection of macrophages
Monocyte-derived macrophages were inoculated with HIV-1Ada
(Vpr+) and (Vpr2) viruses at 4610
6 cpm of RT activity/10
6 cells
in 200 ml of medium, centrifuged for 1 h at 2,000 rpm at room
temperature, and incubated for 3 hours at 37uC, followed by 3
washes with PBS. Infected cells were cultivated in fresh RPMI
1640 complete medium supplemented with 10% human serum.
Every 3–4 days, half of the medium was changed and checked for
p24 activity.
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